InvestorsHub Logo

Whalatane

09/04/19 6:48 PM

#226092 RE: ghmm #226089

ghmm. Yes according to my wife it’s a very buyable argument .
Dialysis patients on phosphate binders ( most are ) complain of constipation ... often only 2-3 bowel movements per week .
When they add Tenapanor bowel movements may increase to 5-6 times a week .
In my wife’s opinion most of her patients would consider this a good thing because it made them feel more “ normal “

The issue will be in the final P3 which is a mono therapy . There won’t be a binder to offset the “ loose stool “ ... so discontinue rate might be higher .

In end wife thinks it will be a blend of the 2 ... allowing patients to reduce the binders they are on when they add Tenapanor .... but not to the extent of causing diarrhea

I posted more on the other board
Kiwi

DewDiligence

09/13/19 11:27 AM

#226172 RE: ghmm #226089

FDA approves ARDX’s Ibsrela (tenapanor) for IBS-C—stock down 13%:

https://finance.yahoo.com/news/ardelyx-receives-fda-approval-ibsrela-191200595.html

Apparently something bad in the label or a kneejerk sell-on-news.

ARDX has said they want a commercial partner for this drug.